The FDA has paused public releases of complete response letters (CRLs) for unapproved drugs as it works to shore up the legal basis for how rejection rationales are disclosed. The agency’s move follows litigation risk concerns around releasing often sensitive information. In parallel, HHS has advanced rulemaking work tied to COVID-19 vaccine injury payments, keeping broader regulatory attention on how agencies handle sensitive determinations. For biotech sponsors, the CRL pause adds uncertainty to disclosure timelines and may affect how companies communicate regulatory status during late-stage development and review cycles.